Healthcap IV Established with Committed Capital of MSEK 3 000

Total Page：16

File Type：pdf, Size：1020Kb

Odlander Fredrikson Group 2002-09-17 PRESS RELEASE HealthCap IV established with committed capital of MSEK 3 000 HealthCap IV was established in the summer of 2002 and now announces its final closing with a committed capital of SEK 3 000 000 000. HealthCap IV is a multi-stage venture capital fund investing in the medical sector. HealthCap invests internationally, with a focus on the Nordic region and Western Europe. The fund invests in commercialisation of medical science and innovations, in newly started companies as well as in more established enterprises. The three previous HealthCap funds will continue to make follow-on investments in existing portfolio companies. More than fifty initial investments have been made by these three funds, of which some 20 in start-up companies. Currently twelve of these companies have publicly quoted shares. HealthCap is seeking active partnership with portfolio companies and founders, providing assistance with inter alia company formation, formulation of strategies, management and financing. Investors in HealthCap IV include the 4th Swedish National Pension Fund, AGF Private Equity, AIG Global Investments, Allianz Private Equity, ATP Private Equity, Barclays Bank UK Retirement Fund, CDP Sofinov, Grove Street Advisors for CalPERS, HarbourVest Partners, MN Services, Swiss Re, Tapiola, TIFF, The Kresge Foundation, Toronto University, Vanderbilt University and Washington University. The Odlander Fredrikson Group is the exclusive investment advisor to the fund. MVision Private Equity Advisers Limited acted as global financial advisors to the Odlander Fredrikson Group, with CSFB and Handelsbanken as regional placing agents, in connection with the placing of the fund. For more information please contact Odlander Fredrikson Group Odlander, Fredrikson & Co AB Odlander Fredrikson SA Björn Odlander Peder Fredrikson tel. +46-8-442 58 59 tel. +41-79-653 26 19 The Odlander Fredrikson Group is a financial advisory firm with expertise in science, medicine and investment banking. Operations are conducted from offices in Stockholm and Lausanne. .

—— Preview end. ——

Copy Link

Recommended publications

Entrepreneurship in Spain
All you need to know about entrepreneurship in Spain June 2021 edition A way to make Europe EUROPEAN REGIONAL DEVELOPMENT1 FUND CONTENT Part I – STARTING POINT • Creating a startup Part II – RESOURCES FOR STARTUPS • Resources for startups • Incubators • Accelerators • Specific services suppliers Part III – FINANCING FOR STARTUPS • How to obtain financing • Private sector • Public sector • European calls • National calls Part IV – EVENTS FOR STARTUPS • Events Part V – AUTONOMOUS REGIONS • Programs and subsidies for startups This guide is intended as a collection of resources for startups in their different stages of seeking public and/or private funding 2 Part I Starting point CREATING A STARTUP IN SPAIN The steps to establish a startup are the same as for any other company. The very first one is to determine the most appropriate legal form, a decision that will be influenced by the startup´s later needs regarding participation deals and receipt of third-party investment. The most used legal forms are: Spain • Limited Liability Company (Sociedad Limitada, S.L.) in • Corporation (Sociedad Anónima, S.A.). startup Both forms can also be set up as a sole-shareholder entity (Sociedad Anónima Unipersonal, S.A.U. and Sociedad Limitada Unipersonal, S.L.U. respectively) a at the time of incorporation or be converted into a sole-shareholder entity afterwards. While there are alternatives to these legal forms, they aren´t advisable for startups that will be seeking to add partners to the project and/or third-party investors. For information purposes, these include: Freelancer (Autónomo), Private partnership (Sociedad Civil) or Jointly-Owned Entity (Comunidad de creating Bienes), or a Cooperative (Cooperativa).
[Show full text]
Article Communicate
article communicate French Chapter of the Venture Capital Handbook for 2011 PLC www.morganlewis.com Venture Capital: France Resource type: Articles: know-how Status: Law stated as at 01-Nov-2010 Jurisdiction: France A Q&A guide to venture capital law in France. The Q&A gives a high level overview of the venture capital market; tax incentives; fund structures; fund formation and regulation; investor protection; founder and employee incentivisation and exits. For a full list of recommended venture capital law firms and lawyers in France, please visit PLC Which lawyer? This Q&A is part of the PLC multi-jurisdictional guide to venture capital. For a full list of jurisdictional Q&As visit www.practicallaw.com/vchandbook. Ann Baker, Anne Tolila, Karen Noël, Olivier Edwards and Olivier Couraud, Morgan Lewis & Bockius Contents Market Tax incentives Fund structure Fund formation and regulation Investor protection Founder and employee incentivisation Exits Contributor details Anne Tolila Karen Noël Ann G Baker Olivier Edwards Market 1. Please describe briefly the venture capital market in your jurisdiction, in particular: How it is distinguished from private equity. The sources from which early stage companies obtain funding. The types of companies that attract venture capital investment. Market trends (for example, levels of investment, the type of companies invested in and where those companies are located). Venture capital and private equity Venture capital distinguishes itself by the: Early stage of development of the companies which are funded. The absence of leverage and consequently of debt in the investment, which is generally made in equity. The following figures and more can be found on www.chaussonfinance.com.
[Show full text]
European Telemedicine
WWW.DRAKESTAR.COM APRIL 2021 6 Sector Report EUROPEAN TELEMEDICINE Christophe Morvan, Managing Partner Lawrence Giesen, Partner christophe.morvan@drakestar.com lawrence.giesen@drakestar.com +33 170 087 610 +33 170 087 613 Grégoire Bizouerne, Analyst Antoine Pigneux, Analyst gregoire.bizouerne@drakestar.com antoine.pigneux@drakestar.com +33 170 087 615 +33 170 087 621 A MESSAGE FROM DRAKE STAR We are pleased to publish the inaugural 2021 Drake Star Telemedicine Sector Report presenting the European telemedicine market during an unprecedented year for the industry due to the ongoing Covid-19 outbreak. Our report will explore the uses of telemedicine, market trends, the impact of the Covid-19 crisis, interviews with leaders in the sector as well as an overview of the European landscape and its main players. We will include an extensive list of the recent private placement and M&A activity as well as an analysis of public markets valuations, including the launch of the Drake Star Telemedicine Index. We also provide 72 short profiles of European telemedicine companies, from startups to established firms, offering a diverse picture of the European market. The global telemedicine market recorded historic growth in 2020, reaching $52bn and is projected to triple by 2025 to over $150bn. Based on our estimations, the European market represents 20% of the global telemedicine market, but growing at a slower rate due to structural issues. Telemedicine adoption has been accompanied by a surge in fundraising, enabling platforms to scale quickly. We provide a mapping of the largest and most active financial and industrial investors in the space.
[Show full text]
Connecting Private Equity and Venture Capital Investment Vehicles to Global Capital Sources the European Private Equity & Venture Capital Web Meeting
Connecting Private Equity and Venture Capital Investment Vehicles to Global Capital Sources The European Private Equity & Venture Capital Web Meeting ZOOM & SLACK July 21st, 22nd & 23rd 2020 Central European Time LIVE ONLY, RECORDING IS PROHIBITED BUSINESS CASUAL ATTIRE The European Private Equity & Venture Capital Web Meeting ZOOM & SLACK– July 21st, 22nd & 23rd 2020 Dear Colleague, It is with great pleasure that I invite you to The European Private Equity & Venture Capital Web Meeting. The aim of this Web Meeting is to connect private equity & venture capital funds, family offices, institutional investors, and other industry professionals across Europe and the world. Our online meeting brings together over 400 c-level executives that will join us to virtually network and discuss investment opportunities, allocations, and the current performance of all private equity & venture capital related asset classes. Panel discussions to be covered include topic on institutional investor, family office, private equity, and venture capital perspectives. This is a live event and closed to the media. Video and audio recording of this event is strictly prohibited. We look forward to hosting you digitally! Best, Roy Carmo Salsinha President, CEO Carmo Companies By the Numbers… In Attendance… $5+ Trillion AUM in attendance • European focused Private • Multi Family Offices Equity Funds and Venture • Government officials 400+ Total participants Capital Funds • Economists 200+ Institutional & Private Wealth Investors • Hedge Funds • • Public Pension Funds Banks and Investment 200+ Private Equity & Venture Capital Funds Banks Managers • Corporate Pensions Funds • Lawyers • Pension Consultants 6 Industry Exclusive Panel Sessions • Auditors • Endowments 6 Hours of private virtual networking/speed dating Executives Level • Commercial Service - C • 3 Day Zoom Web Conference Foundations Providers • Fund of Funds 3 Day Slack networking tool access • Sovereign Wealth Funds • Single Family Offices WEB MEETING APPS • Our Video Conference will be Powered by ZOOM.
[Show full text]
3Rd FCF Life Science Venture Capital Report
FCF Life Science Research 3rd Life Science Venture Capital Report – Financing Trends in Europe and the US Fungi Penicillium Part of FCF Life Science Research Series Executive Summary FCF Overview Funding Development in 2018 Life Sciences: A closer Look C r o s s - border Investment Activity Investor Analysis Life Science Exits 2 Executive Summary The FCF Life Science Venture Capital FCF Life Science Venture Capital Report Recipients Report is a is a comprehensive, standardized analysis for biotechnology, The FCF Life Science Venture Capital Report targets the following standardized report pharmaceutical and medical technology companies, examining recipients: focusing on venture recent venture capital deal trends in the European life science ▪ Corporates / Executives ▪ Venture capital investors capital deal industry ▪ Institutional investors ▪ Family Offices / High- characteristics in the ▪ Private equity investors net-worth individuals biotechnology, ▪ Advisors Selection of Companies pharmaceutical and medical technology The selection of companies is based on the following criteria: Availability segments, and can be used as a quick ▪ Companies operating in the biotechnology, pharmaceutical, The FCF Life Science Venture Capital Report is available on FCF’s reference for medical technology, services or other life science related sectors website at “https://www.fcf.de/de/research/life-science-research“ investors, corporates ▪ Sole focus on transactions involving European life science and professionals companies Data ▪ The therapeutics sector is further divided into the following All input data is provided by Pitchbook, S&P Capital IQ or More advanced, indications: Oncology, Central Nervous System, Infectious GlobalData and is not independently verified by FCF. Ratio and detailed and / or Diseases, Immunology, Ophthalmology, Rare Diseases, multiple calculations are driven based on the input data available.
[Show full text]
Life Sciences Fundraising
Fig. 1: Preqin Research Report - Sept 2009 Aggregate Capital Raised by Life Science Funds Private Equity Life Science Funds (1) 2007-2009 YTD 30 24.2 Life science, also known as Fundraising by Region 25 bioscience, comprises of several 20 branches of science, including Examining pure life science private 15 biology, medicine and ecology. This equity fundraising by regional focus $bn comprehensive scientific division is exposes the dominance of US 10.7 10 emerging as a burgeoning private focused funds in this sector. US 6.4 equity sector with a variety of funds focused life science private equity 5 4.0 2.6 hitting the market looking to invest funds have attracted far more 0.8 in firms that are developing ideas in aggregate capital than their global 0 biotechnology, pharmaceuticals and counterparts for each of the past 2007 2008 2009 YTD biomedical technologies. three years, securing more than $4 Non-Pure Life Science Pure Life Science billion in 2007, $2.4 billion in 2008 This research report contains key and nearly $2.5 billion in 2009. facts and statistics to help you European focused pure life science “ understand more about this growing funds have also had an impact on investment sector. global fundraising, drawing around $1.6 billion in aggregate capital ...The pure life science private equity Aggregate Capital Raised in 2007 and 2008. Fundraising in 2009 year-to-date has proved fundraising market is almost wholly Fig. 1 shows the aggregate capital more of a challenge, with only $70 comprised of venture vehicles... raised by all private equity funds million having been committed to involved with life sciences from life science funds closed so far this “ 2007 to 2009 year-to-date.
[Show full text]
Biotechnology Startups Research Report
GLOBAL BUSINESS CONFIDENCE REPORT 4th Qtr. 2019 B IOTECH NOLOGY STARTUPS RESEARCH REPORT 4th Quarter 2019 www.tradecouncil.org www.qibcertification.org International Trade Council www.tradecouncil.org www.goglobalawards.org Page 1 MARKET OVERVIEW REPORT FOR ENTERPRISE ESTONIA Table of Contents Overview ........................................................................................................................................................................... 3 Industry Definition .......................................................................................................................................................................................... 3 Sectoral Definitions ........................................................................................................................................................................................ 3 Main Activities .................................................................................................................................................................................................. 4 Associated Industries ..................................................................................................................................................................................... 4 Industry at a Glance ......................................................................................................................................................... 5 Industry Overview ..........................................................................................................................................................................................
[Show full text]
Fourth Swedish National Pension Fund – Background
ANNUAL REPORT 2002 1 Fourth Swedish National Pension Fund – Background History The Fourth Swedish National Pension Fund was founded in 1974. Investment goods The Fund is an independent state-owned body charged with managing assets to provide maximum benefit to the income-based retirement pension system. The Fund’s overall investment risk should be low. At the chosen risk level, Fund assets should be invested so as to secure a high long-term return. Board of Directors The Fund’s Board of Directors consists of nine full members, all appointed by the government. Investment rules The Fund’s investment rules in their current form entered force on 1 January 2001 and are as follows: ■ Investments are permitted in all forms of capital market instruments that are listed and liquid. ■ At least 30% of the Fund’s assets must be invested in fixed income securities with low credit and liquidity risk. ■ In 2001, the Fund was permitted to expose 15% of its assets to currency risk. Thereafter the Fund could increase exposure by 5% per annum up to a specified long-term maximum of 40%. ■ No more than 10% of the Fund’s assets may be exposed to a single issuer or group of connected issuers. ■ Equities in listed Swedish companies may not exceed 2% of stock market capitalisation. ■ The Fund may own shares corresponding to no more than 10% of the voting capital in any single listed company. ■ A maximum 5% of the Fund’s assets may be invested in unlisted securities. Such investments must be made indirectly via venture capital firms or similar entities.
[Show full text]
The 29Th Medtech Investing Europe Conference 26 & 27 November 2019 • Bankside Hotel London, UK
The 29th MedTech Investing Europe Conference 26 & 27 November 2019 • Bankside Hotel London, UK Delegate Guide & Programme Speaker Biographies MedTech Presenting Company Information Organised by: In Partnership with: Sponsored by: www.medtechinvesting.com Welcome 26 November 2019 Dear Participant, It gives me great pleasure to welcome you to the 29th MedTech Investing Europe Conference here in London. As always we have a packed conference programme, addressing some of the major challenges and opportunities in the sector today, as well as improved and extended networking opportunities, One- To-One meetings and the all-important Presenting Company streams bringing the latest technologies and investment opportunities. This year we are once again giving audience members the opportunity to vote for the “Best In Show Presenting Company” – with every delegate able to cast 1 vote via the event app and One-To-One networking system, the winner will be announced at the end of the conference. I would like to thank all those who have contributed to the organisation of the conference including our sponsors BioAlps, Canton of Vaud; our partners École Polytechnique Fédérale de Lausanne (EPFL) and of course all of our supporters. We are extremely grateful for the time and preparation our expert panel of speakers have put into being here to share with you their knowledge and expertise. Final thanks must go to the Presenting Companies, who will bring to you genuinely ground-breaking technologies that truly have the potential to be tomorrow’s game-changers. We constantly strive to develop events that reflect the needs of the healthcare sector; events that give essential and timely insight into today’s opportunities and challenges and provide the very best networking opportunities for both investors and technology providers alike.
[Show full text]
Private Equity Market Activity
P e n s i o n C o n s u l t i n g A l l i a n c e, I n c. Los Angeles • Portland • New York Los Angeles Department of Water and Power Employees’ Retirement Plan Private Equity Program Performance Report June 30, 2007 Prepared by: Pension Consulting Alliance, Inc. 0 P e n s i o n C o n s u l t i n g A l l i a n c e, I n c. Los Angeles • Portland • New York Table of Contents Page Program Overview 2 Private Equity Market Overview 3 Evolution and Current Status of the Private Equity Program 6 Investment Performance 7 Portfolio Structure 9 Summary 11 Appendix Tab A Tracking Schedule A-1 Landmark Equity Partners XIII, LP A-2 Lexington Capital Partners VI, LP A-3 Tab B Return Calculation Discussion B-1 1 P e n s i o n C o n s u l t i n g A l l i a n c e, I n c. Los Angeles • Portland • New York Program Overview The Los Angeles Department of Water and Power Employees’ Retirement Plan (“WPERP” or the “Plan”) Private Equity Program consists entirely of secondary market fund-of-funds to date. The Program is very young as the initial commitments to private equity were made in 2006. As private equity partnerships are long-term investments that are invested over several years, the Program is expected to continue to grow and evolve over time. Funding Projections The Program’s current long-term target allocation is 4% of the Plan’s total portfolio representing approximately $324 million in current market value.
[Show full text]
International Corporate Finance M&A • Private Equity • Banking & Finance • Tax • Antitrust
2016 EDITION INTERNATIONAL CORPORATE FINANCE M&A • PRIVATE EQUITY • BANKING & FINANCE • TAX • ANTITRUST Marco De Benedetti The Carlyle Group P. 54 Tania Daguere-Lindbäck Blackstone P. 38 Augusto Lima Anheuser-Busch InBev P. 45 Louis Schweitzer Renault P. 41 Luciane Ribeiro Santander Brasil Asset Management P. 37 Benedict Oramah Afreximbank P. 49 Mathilde Bluteau Microsoft France P. 35 Gaurav Malik Philips Lighting P. 42 Giselle Luna de Mello Wells Fargo GFI RANKINGS P. 51 AMERICAS P.67 EXTERNAL CONTRIBUTORS EXECUTIVE SUMMARY EUROPE P.149 EXPERT VIEWS P.326 THE GLOBAL MARKET: ASIA P.301 Jeff Immelt MONEY TALKS P.12 TOP ADVISORS DIRECTORY Argentina, Brazil, Canada, Chile, Colombia, GE PRIVATE EQUITY FIRMS P.334 Mexico, Peru, Uruguay, USA, Austria, Belgium, 50 LEADERS P. 42 France, Germany, Italy, Luxembourg, Netherlands, INVESTMENT BANKS THE 50 PEOPLE OF THE YEAR Poland, Portugal, Russia, Spain, Switzerland, UK, & FINANCIAL ADVISORS P.337 IN CORPORATE FINANCE P.34 China, India, Japan EXECUTIVE SEARCH & ADVISORY P.341 LAW FIRMS P.342 Customized legal and fi nancial translation services HIGHLY SPECIALIZED LEGAL AND FINANCIAL TRANSLATION SERVICES ■ A skilled, experienced and dynamic team of in-house fi nancial and legal translators ■ Project managers capable of handling all types of projects ■ A network of highly-skilled freelance translators ■ Ability to rapidly meet the constraints of our specialist sectors ■ An in-depth awareness of clients’ needs Legal translation Financial translation ■ Arbitration and litigation ■ Invest ment funds ■ International Trade ■ Banking ■ Corporate fi nance ■ Real Estate ■ Asset Management ■ Mining, Petroleum ■ Private Equity ■ Intellectual Property ■ Information Technology ■ International organisations We specialise in Investment Funds Over the past 10 years, Tradewords has built up a network of leading European fund specia- lists.
[Show full text]
LYZZ Capital 85
Appendix II Top 100 Longevity Investor Profiles 1. ABN AMRO 34. Flagship Pioneering 67. Partners Innovation Fund 2. Accuitive Medical Ventures 35. Forbion Capital Partners 68. Piper Jaffray Private Capital Group 3. Advantech Capital 36. Formation 8 69. Polaris Partners 4. Alexandria Venture 37. GE Capital 70. RA Capital Management 5. Ally Bridge Group 38. GE Ventures 71. Ramius Advisors 6. ALS Finding a cure 39. General Catalyst 72. Sanofi-Genzyme BioVentures 7. AME Cloud Ventures 40. GV 73. Shibuya Kogyo 8. Amino Capital 41. Harvest Global Investments 74. Silicon Valley Bank 9. Ann Arbor SPARK 42. Horizon Ventures 75. Sino-Alliance International LTD 10. ARCH Venture Partners 43. Illumina 76. S.R.I.W 11. Arkin Holdings 44. Integrale Advisors 77. Sphera Funds Management 12. Aspire Capital Partners LLC 45. Inventages Capital Investment inc 78. Springboard Capital 13. ATEL Ventures 46. Jennison Associates 79. StartUp Health 14. BRCC 47. Juno Therapeutics 80. Sutter Hill Ventures 15. Brainchild Holdings 48. Juvenescence Limited 81. SWMF Life Science Fund 16. Cardinal Partners 49. Khosla Ventures 82. Syno Capital 17. Casdin Capital 50. LabCorp 83. Synthetic Genomics 18. Celgene 51. Legend Capital 84. T. Rowe Price 19. CIRM 52. LYZZ Capital 85. Tan Thay 20. Cyberdyne 53. Magic Stone Alternative 86. Techammer 21. Deep Knowledge Life Sciences 54. Mayo Clinic Ventures 87. Techno Venture Management 22. Deerfield Partners 55. Merck Ventures 88. Testudo Funds 23. DeNovo Ventures 56. NanoDimension 89. The Thiel Foundation 24. DFJ 57. Nazem and Company 90. Third Rock Ventures 25. Easton Capital 58. New Science Ventures 91. Toray Engineering 26.
[Show full text]